期刊文献+

两株重组大肠杆菌高密度发酵裂解液澄清工艺研究 被引量:1

Research on Study on Clarification Process of High Density Fermentation Lysate of Two Recombinant Bacterias
下载PDF
导出
摘要 为了减少料液对层析的干扰,降低层析填料的负荷,提高目标蛋白回收率,文章对两株重组大肠杆菌高密度发酵裂解液澄清工艺进行了研究。选取分别表达猪链球菌和副猪嗜血杆菌关键基因的BL21-HP1036、BL21-palA菌株,采用切向流工艺、高速离心工艺和膜包澄清工艺,通过浊度、电泳检测等方法评估蛋白得率。结果表明:采用膜包过滤清液和膜包浓缩液离心两步法对分别表达猪链球菌和副猪嗜血杆菌关键基因的BL21-HP1036、BL21-palA高密度发酵裂解菌液进行澄清,蛋白得率80%以上,可有效减少层析干扰,提高回收率。 In order to reduce the interference of feed liquid to chromatography,reduce the packing load of chromatography,improve the recovery rate of target protein,this paper studied the clarification process of high-density fermentation lysates of streptococcus suis and Haemophilus parasuis Escherichia coli.The recombinant bacteria BL21-HP1036 and BL21-palA were selected,and the protein yield was evaluated by turbidity,and electrophoresis.The results show that:using membrane filtration clear liquid and membrane concentration liquid centrifugation two-step to study the proteins content of BL21-HP1036 and BL21-palA,the protein yield is more than 80%,which could effectively reduce the chromatography interference and improve the recovery rate.
作者 任培森 吕文静 郑新勇 刘海霞 王艳晓 朱秀同 Ren Peisen;Lyu Wenjing;Zheng Xinyong;Liu Haixia;Wang Yanxiao;Zhu Xiutong(Tianjin Ringpu Biotechnology Co.,Ltd.,Tianjin 300381,China)
出处 《农业技术与装备》 2022年第6期120-122,共3页 Agricultural Technology & Equipment
关键词 重组大肠杆菌 亚单位疫苗 微滤膜包 澄清工艺 recombinant escherichia coli subunit vaccine microfiltration membrane package clarification process
  • 相关文献

参考文献1

二级参考文献34

  • 1Chae C. A review of porcine circovirus 2-associated syndromes and diseases [J]. Vet J , 2005 , 169(3) : 326-336.
  • 2Zhai S L , Chen S N , Xu Z H , et al. Porcine cireovirus type 2 in China: an update on and insights to its prevalence and control [J]. VirolJ , 2014 , 11 : 88.
  • 3Khayat R , Brunn N , Speir J A , et al. The 2. 3-angstrom struc-ture of porcine circovirus 2 [ Jl. J Virol, 2011, 85 (15) : 7856 -7862.
  • 4Opriessnig T , Patterson A R , Madson D M , et al. Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV-PCV2-SIV clinical infection model 2-3-months post vaccination [J]. Vaccine, 2009, 27(7): 1002-1007.
  • 5Huang L , Lu Y , Wei Y , et al. Development of a blocking ELISA for detection of serum neutralizing antibodies against porcine circovir- us type2 [J]. JVirolMethods, 2011, 171(1) : 26-33.
  • 6Seo H W, Han K, Park C, et al. Clinical, virological, immunologi- cal and pathological evaluation of four porcine circovirus type 2 vac- cines [J]. Vet J, 2014, 200(1) : 65-70.
  • 7Huang C J , Lin H , Yang X. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements [ J]. J Ind Microbiol Biotechnol, 2012, 39(3): 383-399.
  • 8Shuai J, Zhang X, Chen W, et al. In vivo characterization of chime- ric PCV DNA clones containing heterogeneous capsid protein nuclear localization signals(NLS) EJ~. Virol J, 2013, 10: 16.
  • 9Wu P C, Lin W L, Wu C M, et al. Characterization of porcine cir- covirus type 2 ( PCV2 ) capsid particle assembly and its application to virus-like panicle vaccine development [ J ]. Appl Microbiol Bio- technol, 2012, 95(6) : 1501-1507.
  • 10Zhou J Y, Shang S B, Gong H, et al. In vitro expression, mono- elonal antibody and bioactivity for capsid protein of porcine eireovims type II without nuclear localization signal [ J]. J Bioteehnol, 2005, 118(2) : 201-211.

共引文献6

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部